PharmaCyte is a clinical stage biotechnology company developing therapies for cancer and diabetes based upon a proprietary cellulose based live cell encapsulation technology known as Cell in a Box. This technology will be used as a platform upon which therapies for several types of cancer and diabetes are being developed. For cancer, the therapy involves encapsulating genetically engineered human cells that convert the prodrug ifosfamide from its inactive form to its cancer killing form. These encapsulated live cells are implanted in a patient as close to the tumor as possible. Then ifosfamide is given IV at one third the normal dose. When the ifosfamide comes in contact with the encapsulated live cells, they act as an artificial liver where ifosfamide is normally activated and activate the ifosfamide at the source of the cancer. For diabetes, PharmaCyte is developing a treatment for Type diabetes and insulin dependent Type diabetes. PharmaCyte plans to encapsulate a human cell line that has been genetically engineered to produce, store and release insulin in response to the levels of blood sugar in the human body. PharmaCyte is also exploring the use of beta islet cells to treat Type and insulin dependent Type diabetes. The encapsulation of these cells will be done using the Cell in a Box technology. Once the encapsulated cells are implanted in a diabetic patient they will function as a bio artificial pancreas for purposes of insulin production.
Quote | PharmaCyte Biotech Inc. (OTCMKTS:PMCB)
Last: | $3.03 |
---|---|
Change Percent: | -56.71% |
Open: | $3.08 |
Close: | $3.03 |
High: | $3.14 |
Low: | $2.92 |
Volume: | 1,774,614 |
Last Trade Date Time: | 08/10/2021 04:41:14 am |
News | PharmaCyte Biotech Inc. (OTCMKTS:PMCB)
2024-03-19 06:53:28 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips PharmaCyte Biotech (NASDAQ: PMCB ) just reported results for the third quarter of 2024. PharmaCyte Biotech reported earnings per share of -65 cents. The company did no...
2023-12-18 11:51:33 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips PharmaCyte Biotech (NASDAQ: PMCB ) just reported results for the second quarter of 2024. PharmaCyte Biotech reported earnings per share of -26 cents. The company did n...
Message Board Posts | PharmaCyte Biotech Inc. (OTCMKTS:PMCB)
Subject | By | Source | When |
---|---|---|---|
Maybe Iroquois forgot they have $PMCB. | Diana15 | investorshub | 04/26/2023 6:34:27 PM |
I believe. | saladan2 | investorshub | 04/22/2023 9:34:31 PM |
I agreed and copy that | $Pistol Pete$ | investorshub | 04/12/2023 6:13:38 PM |
Believe or not, Iroquois is worst than Kenny | Diana15 | investorshub | 04/11/2023 9:12:12 AM |
lmao | longboarder7892 | investorshub | 04/10/2023 11:55:53 PM |
News, Short Squeeze, Breakout and More Instantly...
PharmaCyte Biotech Inc. Company Name:
PMCB Stock Symbol:
OTCMKTS Market:
PharmaCyte Biotech Inc. Website:
Epiroc AB ADR (EPOKY) is expected to report for Q3 2023 Sysmex Corporation ADR (SSMXY) is expected to report for Q2 2024 Streamline Health Solutions Inc. (STRM) is expected to report for Q1 2024 Helix Biopharma Corp. (HBPCF) is expected to report for Q2 2024 Standard Chartered plc...